Comparison of glucose variability assessed by a continuous glucose-monitoring system in patients with type 2 diabetes mellitus switched from NPH insulin to insulin glargine: The COBIN2 study

Wiener Klinische Wochenschrift

Volumn 126, Issue 7-8, 2014, Pages 228-237

  Zdarska, Denisa Janickova ^a   Kvapil, Milan ^a   Rusavy, Zdenek ^b   Krcma, Michal ^b   Broz, Jan ^a   Krivska, Bohumila ^c   Kadlecova, Pavla ^d  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c Sanofi aventis sro   (Czech Republic)

^d ADDS sro   (Czech Republic)

Author keywords

Continuous glucose monitoring system; Glucose variability; Insulin glargine; Type 2 diabetes mellitus

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; ISOPHANE INSULIN; METFORMIN; SULFONYLUREA; ANTIDIABETIC AGENT; GLARGINE; GLUCOSE BLOOD LEVEL; LONG ACTING INSULIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTHRALGIA; ARTHROPOD DISEASE; ARTICLE; BLOOD GLUCOSE MONITORING; CIRCADIAN RHYTHM; CONTINUOUS GLUCOSE MONITORING SYSTEM; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSECT ALLERGY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOARTHRITIS; PARESTHESIA; PERIPHERAL EDEMA; PROSPECTIVE STUDY; ADOLESCENT; ANALYSIS; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CZECH REPUBLIC; DIABETES MELLITUS, TYPE 2; DRUG MONITORING; MIDDLE AGED; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; CZECH REPUBLIC; DIABETES MELLITUS, TYPE 2; DRUG MONITORING; DRUG SUBSTITUTION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, ISOPHANE; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84901252313     PISSN: 00435325     EISSN: 16137671     Source Type: Journal    
DOI: 10.1007/s00508-014-0508-6     Document Type: Article

References (17)

1. Hirsch IB, Brownlee M. Should minimal blood glucose variability become the gold standard of glycemic control? J Diabetes Complications. 2005;19(3):178-81. (Pubitemid 40615551)
2. Danielson P, Truedsson L, Eriksson KF, Norgren L. Inflammatory markers and IL-6 polymorphism in peripheral disease with and without diabetes mellitus. Vasc Med. 2005;10(3):191-8. (Pubitemid 41479673)
3. Cohen MP, Shea E, Chen S, Shearman CW. Glycated albumin increases oxidative stress, activates NF-kappa B and extracellular signal-regulated kinase (ERK), and stimulates ERK-dependent transforming growth factor-beta 1 production in macrophage RAW cells. J Lab Clin Med. 2003;141(4):242-9. (Pubitemid 36432924)
4. Taguchi T, Brownlee M. The biochemical mechanisms of diabetic tissue damage. In: Pickup J, Williams G, editors. Textbook of diabetes. 3rd ed. Oxford: Blackwell Science; 2003.
5. Qualiaro L, Piconi L, Assalone R, Martinelli L, Motz E, Ceriello A. Intermitent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role o protein kinase C and NAD(P)H-oxidase activation. Diabetes. 2003;52:2795-804. (Pubitemid 37339710)
6. Hanefeld M, Fischer S, Julius U, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia. 1996;39(12):1577-83. (Pubitemid 26397370)
7. Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000;49(12):2142-8.
8. Owens D, Coates P, Luzio S, Tinbergen JP, Kurzhals R. Pharmacokinetics of 125I-labeled insulin glarginee (HOE 901) in healthy men. Diabetes Care. 2000;23(6):813-9.
9. Yki-Järvinen H, Dressler A, Zieman M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care. 2000;23(8):1130-6. (Pubitemid 30616801)
10. Kovatchev B, Anderson S, Heinemann L, Willim C. Comparison of the numerical and clinical accuracy of four continuous glucose monitors. Diabetes Care. 2008;31:1160-4.
11. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837-53.
12. Stettler C, Allemann S, Jüni P, Cull CA, Holman RR, et al. Glycemic control and macrovascular disease in type 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am Heart J. 2006;152:27-38. (Pubitemid 43974725)
13. Monnier L, Colette C, Owens DR. Integrating glycaemic variability in the glycaemic disorder of type 2 diabetes: a move towards a unified glucose tetrat concept. Diabetes Metab Res Rev. 2009;25(5):393-402.
14. Buscemi S, Re A, Batsis JA, et al. Glycaemic variability using continuous glucose monitoring and endothelial function in the metabolic syndrome and in type 2 diabetes. Diabet Med. 2010;27(8):872-8.
15. Ceriello A. Hyperglycaemia and the vessel wall: the pathophysiological aspects on the atherosclerotic burden in patients with diabetes. Eur J Cardiovasc Prev Rehabil. 2010;17(Suppl. 1):S15-9.
16. Wright RJ, Frier BM. Vascular disease and diabetes: is hypoglycaemia an aggravating factor? Diabetes Metab Res Rev. 2008;24:353-63.
17. Hahn, GJ, Meeker WQ. Statistical intervals: a guide for practitioners. New York: John Wiley & Sons; 1991.